Skip to main content

Table 2 In vitro cytotoxicity of sorafenib, sunitinib, irinotecan and SN-38 against three AT/RT cell lines

From: Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Inhibitor, IC50 (μM)

BT 12

BT 16

KCCF1

Sorafenib

3.3

2.8

3.6

Sunitinib

3.2

3.2

3.7

Irinotecan

2.0

4.1

6.7

SN-38

0.09

0.03

4.6

  1. IC50 - half maximal inhibitory concentration